The impact of the GLP-1 RA semaglutide (plus maximum tolerated RAAS inhibitor) on kidney and CV outcomes is being investigated in the ongoing phase 3 FLOW clinical trial in patients with T2D and CKD (NCT0381915) (Table 3). This evidence concerns the gene GLP1R and chronic kidney disease.